Rhythm launches IMCIVREE in Japan for acquired hypothalamic obesity
Rhythm Pharmaceuticals announced the commercial launch of IMCIVREE (setmelanotide) in Japan for patients with acquired hypothalamic obesity.
Story updates
11:30:08 PM UTC
SquawkNews
Rhythm Pharmaceuticals Announces Commercial Launch Of IMCIVREE(R) (setmelanotide) In Japan For Patients With Acquired Hypothalamic Obesity >RYTM
11:32:12 PM UTC
SquawkNews
Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list ---- IMCIVREE is the first approved therapy in Japan for patients living with acquired hypothalamic obesity --BOSTON, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Rh…